Search the Newsreel

Immunic (IMUX) director Elena Ridloff receives 50,740 stock options at $14.54

Immunic (IMUX) director Elena Ridloff was granted 50,740 stock options on August 6, 2026, with an exercise price of $14.54 per share. These options, which vest monthly over three years and expire on August 6, 2036, significantly increase her direct holdings. The transaction was …

Immunic appoints Elena Ridloff to board of directors By Investing.com

Immunic, Inc. has appointed Elena Ridloff to its board of directors, effective Wednesday. Ridloff brings over 20 years of experience in finance, corporate development, and capital markets within the biopharmaceutical industry. Immunic is a late-stage biotechnology company developing oral therapies for neurologic diseases and …

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the company's stock on August 7th for over $397,000, reducing his direct holdings by 17.39%. This sale was part of a pre-arranged Rule 10b5-1 plan, and he has sold more than 320,000 shares since late …

Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus

This article highlights several technology and growth companies, including Archer Aviation (ACHR), ImmunityBio (IBRX), Sphere 3D Corp. (ANY), Graphene Manufacturing Group (GMG), and Socket Mobile (SCKT), which are attracting investor attention due to recent corporate, technology, and strategic developments. Archer Aviation is expanding its …

Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT

Hennion & Walsh Asset Management Inc. significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 32.6% in the second quarter, now holding 120,686 shares valued at $4.65 million. Despite this institutional confidence and a "Moderate Buy" consensus rating from analysts, Immunovant reported a wider-than-expected …

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore Holdings (IMCR) presents a trade-off between its growing Kimmtrak product revenue and a premium valuation. While Kimmtrak's sales are strong and late-stage studies could expand its market, the company's reliance on a single product and higher-than-average valuation metrics pose risks. Analysts currently recommend …

ImmunityBio appoints Jim Yong Kim as vice chairman

ImmunityBio, Inc. (NASDAQ:IBRX) has announced the appointment of Dr. Jim Yong Kim as vice chairman, who will focus on international partnerships and global access initiatives within the newly created Office of the Executive Chairman. Dr. Kim, a former president of the World Bank Group …

Scinai Names Eran Kuratz to Lead CDMO Supply Chain and Business Processes

Scinai Immunotherapeutics Ltd. has appointed Eran Kuratz as the head of supply chain and business process administration for its Scinai Biopharma Services subsidiary. This strategic move aims to strengthen operational leadership and integrate the company's expanded contract development and manufacturing organization (CDMO) across its …

MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS

MoonLake Immunotherapeutics (MLTX) deepens loss but ends H1 2026 with $537M cash and key Phase 3 wins

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Scinai Immunotherapeutics has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration for its CDMO subsidiary, Scinai Biopharma Services. This appointment aims to strengthen operational infrastructure and support the integration and scaling of Scinai's expanded CDMO platform, which now includes two …

ImmuPharma, ValiRx, Tertiary Minerals, Caledonia Mining, Sintana Energy - Small Cap Snapshot

ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for …

Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates

HC Wainwright Estimates Immuneering Q3 Earnings

Immunocore Holdings (IMCR) Posted Strong Earnings, Is The 49% Undervaluation Case Convincing?

Price to sales forward of Immunome, Inc. – NASDAQ:IMNM

This article displays the "Price to sales forward" metric for Immunome, Inc. (NASDAQ: IMNM) on TradingView. It presents financial data for the company, indicating the value, change, and percentage change for this specific financial ratio. The content is primarily a data point rather than …

ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach

ImmunityBio (IBRX) is under investor scrutiny after receiving marketing authorization in the UAE for ANKTIVA, used for bladder cancer and lung cancer. While the stock has seen significant year-to-date gains, its current valuation reflects rich revenue multiples and ongoing losses. Analysts present mixed views, …

AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

AC Immune SA reported a significant earnings miss for its latest quarter, with revenues of CHF15m and EPS of CHF0.02 falling short of analyst expectations. Following these results, analysts have revised their forecasts, increasing revenue estimates for 2026 to CHF45.7m but also projecting higher …

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates

Lyell Immunopharma (NASDAQ: LYEL) reported second-quarter earnings per share of $-1.920, exceeding analyst estimates by $0.22. However, the company's revenue of $4K fell short of the consensus estimate of $5.5K. Despite a 23.580% drop in its stock price over the last three months, Lyell …

Immunocore Holdings PLC (IMCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Immunocore Holdings plc (IMCR) Stock Price, News, Quote & History

Immunocore Holdings plc (IMCR) stock information is provided, including its current price of $34.56, up 1.71% in after-hours trading. The company, headquartered in the UK, focuses on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune conditions, with its lead product KIMMTRAK approved for …

Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

ImmunityBio (IBRX) saw its stock rise by 6.6% following its Q2 2026 results and the expanded UAE marketing authorization for its immunotherapy ANKTIVA, now covering bladder and lung cancer in 34 countries. Despite increased revenue, the company reported wider net losses, highlighting the challenge …

ImmuPharma plc Revenue Breakdown – LSE:IMM

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS

ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ImmuCell Corp (ICCC), including future estimates for EPS and revenue growth. It presents current stock performance data, market capitalization, and indicates that the financial forecasts were updated on August 8, 2026. The content also lists peer comparisons …

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock

Estrella Immunopharma Inc (ESLA) Stock News Today

This article provides current stock information for Estrella Immunopharma Inc (ESLA), noting its recent price of $0.723 USD, a drop of 4.01%. It mentions that news and analysis, financials, stock score, technical forecast, ownership, dividends, and profile information are available, with more news expected …

ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value

ImmunityBio (IBRX) has shown strong stock performance with a 321.9% gain over three years, driven by recent approvals for ANKTIVA. However, the stock appears overvalued based on its current Price-to-Sales (P/S) ratio of 46.8x, significantly higher than the biotech industry average. While there is …

Immutep Ltd (IMMP) Stock News Today

This article provides a brief update on Immutep Ltd (IMMP) stock news. It states that more news will be coming soon regarding the company's earnings, analyst ratings, and key developments. The page also displays current stock information for IMMP, including its price, daily change, …

Scinai Immunotherapeutics Ltd (SCNI) Stock News Today

This article provides an overview of Scinai Immunotherapeutics Ltd (SCNI) stock information from TradingKey. It shows the current stock price, recent performance, market capitalization, and various financial and analytical tools available on the platform. The news section indicates that more updates are expected soon.

Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no specific earnings forecast score is available for the company, contrasting with the Biotechnology & Medical Research industry average. It highlights the current stock price, market capitalization, and indicates that relevant …

Altimmune, Inc. (ALT) options chain – Yahoo Finance

This article displays the options chain for Altimmune, Inc. (ALT) as of August 7, 2026. It includes detailed call and put option data such as strike prices, last prices, changes, volume, and open interest for August 21, 2026, expiry. The current stock price and …

Immutep Ltd (IMMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

Immunocore (IMCR) reported a Q2 2026 loss of 2 cents per share, wider than analyst estimates, despite revenues of $115.9 million, which beat expectations and increased 18.3% year-over-year. The revenue growth was primarily driven by strong sales of its drug Kimmtrak in the U.S. …